D&D Pharmatech Inc. (KOSDAQ:347850)
South Korea · Delayed Price · Currency is KRW 74,000
+5,300 (7.71%)
Apr 10, 2026, 3:30 PM KST
D&D Pharmatech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,298 | 11,437 | 18,677 | 610.57 | 1,364 | |
Revenue Growth (YoY) | -62.42% | -38.77% | 2958.97% | -55.24% | - |
Cost of Revenue | 25.58 | 19.67 | 21.35 | 31.36 | 26.09 |
Gross Profit | 4,272 | 11,417 | 18,656 | 579.21 | 1,338 |
Selling, General & Admin | 7,704 | 8,126 | 8,427 | 9,287 | 8,823 |
Research & Development | 25,050 | 23,291 | 19,973 | 47,125 | 56,826 |
Amortization of Goodwill & Intangibles | 3,413 | 3,273 | 3,133 | 10,923 | 9,690 |
Other Operating Expenses | 809.01 | 365.69 | 336.28 | 266.34 | 304.96 |
Operating Expenses | 38,265 | 36,434 | 32,142 | 69,232 | 77,015 |
Operating Income | -33,993 | -25,017 | -13,486 | -68,653 | -75,677 |
Interest Expense | -470.6 | -614.83 | -1,427 | -2,959 | -1,012 |
Interest & Investment Income | 861.83 | 1,114 | 570.24 | 729.08 | 259.37 |
Earnings From Equity Investments | -4,815 | 1,839 | -1,787 | -9,148 | - |
Currency Exchange Gain (Loss) | -174.51 | 579.45 | 405.96 | -670.81 | 244.8 |
Other Non Operating Income (Expenses) | 13,690 | 1,060 | 15,721 | 15,387 | 4,137 |
EBT Excluding Unusual Items | -24,901 | -21,039 | -2.36 | -65,315 | -72,047 |
Impairment of Goodwill | - | - | - | -27,421 | - |
Gain (Loss) on Sale of Assets | -0.14 | -118.38 | -84.78 | 21,524 | - |
Asset Writedown | - | -9,199 | 4,582 | -92,301 | - |
Pretax Income | -24,901 | -30,357 | 4,494 | -163,513 | -72,047 |
Income Tax Expense | -921.61 | -873.72 | 1,068 | -26,487 | -2,185 |
Earnings From Continuing Operations | -23,980 | -29,483 | 3,427 | -137,025 | -69,862 |
Minority Interest in Earnings | 425.1 | 860.63 | 507.26 | 958.94 | 1,638 |
Net Income | -23,555 | -28,623 | 3,934 | -136,067 | -68,224 |
Net Income to Common | -23,555 | -28,623 | 3,934 | -136,067 | -68,224 |
Shares Outstanding (Basic) | 43 | 41 | 36 | 32 | 32 |
Shares Outstanding (Diluted) | 43 | 41 | 38 | 32 | 33 |
Shares Change (YoY) | 6.21% | 8.05% | 16.38% | -2.05% | 12.66% |
EPS (Basic) | -547.00 | -706.00 | 110.37 | -4220.39 | -2120.83 |
EPS (Diluted) | -547.00 | -706.00 | 110.37 | -4220.50 | -2173.66 |
Free Cash Flow | -21,203 | -22,201 | -9,163 | -53,795 | -53,560 |
Free Cash Flow Per Share | -492.40 | -547.60 | -244.19 | -1668.57 | -1627.16 |
Gross Margin | 99.41% | 99.83% | 99.89% | 94.86% | 98.09% |
Operating Margin | -790.97% | -218.74% | -72.21% | -11244.15% | -5547.71% |
Profit Margin | -548.09% | -250.27% | 21.06% | -22285.31% | -5001.38% |
Free Cash Flow Margin | -493.38% | -194.12% | -49.06% | -8810.69% | -3926.36% |
EBITDA | -28,462 | -19,490 | -9,058 | -54,914 | -63,776 |
EBITDA Margin | - | -170.42% | -48.50% | - | - |
D&A For EBITDA | 5,531 | 5,527 | 4,428 | 13,739 | 11,901 |
EBIT | -33,993 | -25,017 | -13,486 | -68,653 | -75,677 |
EBIT Margin | - | -218.74% | -72.21% | - | - |
Effective Tax Rate | - | - | 23.76% | - | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.